Peter H. Hwang
Industry Relationships
Stanford physicians and scientists may interact with the pharmaceutical, biotech, or medical device industries to help develop new medical drugs, devices or diagnostics or to provide medical education about health care related topics of mutual interest. Their interactions are reviewed annually as part of Stanford University School of Medicine policy. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company to physicians and faculty scientists from companies or other commercial entities with which they interact as part of their professional activities. These payments, including cash, equity, equity options and royalties can arise from a variety of activities including consulting, services on boards, educational activities and licensing agreements. In providing this information, Stanford tries to be as informative as possible concerning its faculty's interactions with industry. The following relationships have been reported with the companies listed below during the calendar year 2008. To learn more about Stanford's policies on collaborations with industry go to http://med.stanford.edu/coi
Consulting: Dr. Hwang receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
- Sinexus, Inc.
Royalty Payments: Dr. Hwang consults for and receives royalty payments of $5,000 or more for inventions or discoveries related to the following companies:
- None
Equity: Dr. Hwang owns stock or stock options (if the equity is valued at $5,000 or more, and the company is publicly traded and/or equity if the company is privately held) in the following companies for activities as a founder, inventor, or consultant:
- Sinexus, Inc.
Service on Board of Directors: Dr. Hwang serves in a fiduciary capacity, such as an officer or director, for the following companies or other entities:
- None
Help